IGYXOS
Igyxos’ mission is to develop innovative new pharmaceuticals and medical technologies in the field of human fertility. Igyxos is involved in all phases of development, from the discovery of promising targets to the identification of potential lead compounds such as small molecules and antibodies, and the acquisition of intellectual property rights to drugs and technologies that can then be brought to the development phase. Igyxos also support the transfer of potential drug candidates to pre-clinical and clinical phases of drug development.
IGYXOS
Social Links:
Industry:
Biotechnology Pharmaceutical
Founded:
2017-01-01
Address:
Nouzilly, Centre, France
Country:
France
Website Url:
http://www.igyxos.com
Total Employee:
1+
Status:
Active
Contact:
+ 33 2 47 42 79 57
Email Addresses:
[email protected]
Total Funding:
7.5 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon Content Delivery Network Euro Google Apps For Business Google GStatic Google Static Content
Similar Organizations
Allcyte
Allcyte is a biotech start-up focused on precision medicine and drug development in a patient-centric way using high-content imaging and AI
Current Employees Featured
Founder
Investors List
GO CAPITAL
GO CAPITAL investment in Series A - Igyxos
Bpifrance
Bpifrance investment in Series A - Igyxos
Sofimac Innovation
Sofimac Innovation investment in Series A - Igyxos
Official Site Inspections
http://www.igyxos.com Semrush global rank: 5.93 M Semrush visits lastest month: 1.39 K
- Host name: 147.62.236.23.bc.googleusercontent.com
- IP address: 23.236.62.147
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Igyxos"
Igyxos - Crunchbase Company Profile & Funding
Igyxos’ mission is to develop innovative new pharmaceuticals and medical technologies in the field of human fertility. Igyxos is involved in all phases of development, from the discovery of …See details»
About Us | Igyxos Biotherapeutics
Igyxos was spun out of RetroPharm in 2017 to develop this new class of infertility treatment for humans. Igyxos has successfully raised Series A funding to support the advancement of our clinical development program. Investors include BPI …See details»
Igyxos Company Profile - Office Locations, Competitors, Revenue …
Igyxos is a biotech startup developing pharmaceuticals and medical technologies in the field of human fertility. The Company is involved in all phases of development, from the discovery of …See details»
Igyxos News | Igyxos Biotherapeutics
Dec 19, 2024 Igyxos Biotherapeutics Strengthens Its Leadership Team with the Appointments of Florent Ferré as CEO and Dr. Elke Bestel as Chief Medical Officer. Tours, December 19, 2024 …See details»
Igyxos - Products, Competitors, Financials, Employees, …
Igyxos is a biotechnology company focused on developing novel therapeutics for infertility treatment. Use the CB Insights Platform to explore Igyxos's full profile. Igyxos - Products, …See details»
Igyxos Biotherapeutics Company Profile 2024: Valuation, Funding ...
Igyxos Biotherapeutics was founded in 2017. Where is Igyxos Biotherapeutics headquartered? Igyxos Biotherapeutics is headquartered in Nouzilly, France. What is the size of Igyxos …See details»
Igyxos - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Organization. Igyxos . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Active Tech Count 33. Monthly Visits 43. …See details»
Igyxos - Crunchbase
Igyxos is a biotech startup developing a new treatment for female and male infertility that works by shifting hormal imbalances. Search Crunchbase. Start Free Trial . Chrome Extension. …See details»
Igyxos - VentureRadar
Igyxos Biotherapeutics is dedicated to revolutionizing infertility treatment through groundbreaking science. By leveraging monoclonal antibodies, the company aims to enhance the activity of …See details»
Igyxos Biotherapies | The Pharmaletter
Dec 23, 2024 Igyxos Biotherapies. A biotech company developing a new class of monoclonal antibodies for infertility. Founded in 2017 by Igyxos Chief Scientific Officer Dr. Marie-Christine …See details»
Igyxos Biotherapeutics strengthens leadership team
Dec 19, 2024 We congratulate Florent and Elke and wish them great success in their new role,” said Igyxos chairman Sylvie Bove. Business backgrounds. This article is accessible to …See details»
Igyxos - EU-Startups
Mar 21, 2019 Igyxos is a biotech startup developing a new treatment for female and male infertility that works by shifting hormal imbalances.See details»
Partners | Igyxos Biotherapeutics
In 2020, Selexis and Igyxos entered into a service agreement to utilize Selexis’ proprietary SUREtechnology Platform™ to rapidly develop the cell line to advance the program in human …See details»
Igyxos and Selexis Enter Service Agreement to Advance Igyxos’ …
Sep 2, 2020 Geneva, Switzerland, and Nouzilly, France - September 2, 2020 - Selexis SA and Igyxos announced today that they have entered into a service agreement to develop Igyxos’ …See details»
French biotech startup Igyxos raises €7.5 million Series A to …
Mar 21, 2019 The funding will allow Igyxos to finance the development of its drug candidate until proof of concept in clinical settings. “We are very excited to support the Igyxos team in the …See details»
Latest News | Igyxos Biotherapeutics
Jul 10, 2024 Igyxos and Selexis enter service agreement to advance Igyxos’ first-in-class monoclonal antibody for the treatment of human infertility. SEP02. 2020. Newsroom Latest …See details»
Igyxos and Selexis Enter Service Agreement to Advance Igyxos’ …
Sep 2, 2020 Geneva, Switzerland, and Nouzilly, France, September 2, 2020 – Selexis SA and Igyxos announced today that they have entered into a service agreement to develop Igyxos’ …See details»
Igyxos' New Innovation Could Help Tackle Male Infertility for
Scientists at Igyxos Biotherapeutics, an emerging biopharmaceutical company specializing in infertility solutions, are developing a novel therapeutic addressing both female and male …See details»